Immune Tolerance Therapy in Patients with Acquired Hemophilia

References

• Cohen, A.J. and Kessler, C.M. (1996) "Acquired inhibitors", Bailliere's Clin. Haematol. 9, 331–354.
   PubMed Web of Science ®Google Scholar
• Hay, C.R. (1998) "Acquired haemophilia", Bailliere's Clin. Haematol. 11, 287–303.
   Google Scholar
• Lottenberg, R., Kentro, T.B. and Kitchens, C.S. (1987) "Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy", Arch. Intern. Med. 147, 1077–1081.
   PubMed Web of Science ®Google Scholar
• Green, D. and Lechner, K. (1981) "A survey of 215 non-hemophilic patients with inhibitors to Factor VIII", Thromb. Haemost. 45, 200–203.
   PubMed Web of Science ®Google Scholar
• Bouvry, P. and Recloux, P. (1994) "Acquired hemophilia", Haematologica 79, 550–556.
   PubMed Web of Science ®Google Scholar
• Morrison, A.E., Ludlam, C.A. and Kessler, C. (1993) "Use of porcine factor VIII in the treatment of patients with acquired hemophilia", Blood 81, 1513–1520.
   PubMed Web of Science ®Google Scholar
• Boggio, L.N. and Green, D. (2001) "Acquired hemophilia", Rev. Clin. Exp. Hematol. 5, 389–404.
   PubMedGoogle Scholar
• Kadir, R.A. and Aledort, L.M. (2000) "Obstetrical and gynaecological bleeding: a common presenting symptom", Clin. Lab. Haematol. 22\(Suppl. 1), 12–16.
   PubMedGoogle Scholar
• Kashyap, R., Choudhry, V.P., Mahapatra, M., Chumber, S., Saxena, R. and Kaul, H.L. (2001) "Postpartum acquired haemophilia: clinical recognition and management", Haemo-philia 7, 327–330.
   PubMed Web of Science ®Google Scholar
• Sallah, S. (1997) "Inhibitors to clotting factors", Ann. Hematol. 75, 1–7.
   PubMed Web of Science ®Google Scholar
• Von Depka, M. (2002) "NovoSeven: mode of action and use in acquired haemophilia", Intensive Care Med. 28\(Suppl. 2), S222—S227.
   PubMedGoogle Scholar
• DiMichele, D. (2003) "Immune tolerance therapy dose as an outcome predictor", Haemophilia 9, 382–386.
   PubMed Web of Science ®Google Scholar
• Brackmann, H.H. and Gormsen, J. (1977) "Massive factor-VIII infusion in haemophiliac with factor-VBI inhibitor, high responder", Lancet 2, 933.
   PubMed Web of Science ®Google Scholar
• DiMichele, D.M. (2002) "Inhibitors: resolving diagnostic and therapeutic dilemmas", Haemophilia 8, 280–287.
   PubMed Web of Science ®Google Scholar
• Nemes, L. and Pitlik, E. (2000) "New protocol for immune tolerance induction in acquired hemophilia", Haematologica 85, 64–68.
   PubMedGoogle Scholar
• Fulcher, C.A., de Graaf, MS. and Zimmerman, T.S. (1987) "FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting", Blood 69, 1475–1480.
   PubMed Web of Science ®Google Scholar
• Hoyer, LW., Gawryl, MS. and de la Fuente, B. (1984) "Immunochemical characterization of factor VBI inhibi-tors", Prog. Clin. Biol. Res. 150, 73–85.
   PubMedGoogle Scholar
• Hoyer, LW. and Scandella, D. (1994) "Factor VBI inhibitors: structure and function in autoantibody and hemophilia A patients", Semin. Hematol. 31, 1–5.
   PubMed Web of Science ®Google Scholar
• Pruthi, R.K. and Nichols, W.L. (1999) "Autoimmune factor VIII inhibitors", Curr. Opin. Hematol. 6, 314–322.
   PubMedGoogle Scholar
• Scandella, D., Mattingly, M., de Graaf, S. and Fulcher, C.A. (1989) "Localization of epitopes for human factor VBI inhibitor antibodies by immunoblotting and antibody neutralization", Blood 74, 1618–1626.
   PubMed Web of Science ®Google Scholar
• Scandella, D., Gilbert, G.E., Shima, M., Nakai, H., Eagleson, C., Felch, M., Prescott, R., Rajalakshmi, K.J., Hoyer, LW. and Saenko, E. (1995) "Some factor VBI inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospho-lipid-binding site", Blood 86, 1811–1819.
   PubMed Web of Science ®Google Scholar
• Algiman, M., Dietrich, G., Nydegger, U.E., Boieldieu, D., Sultan, Y. and Kazatchkine, M.D. (1992) "Natural antibodies to factor VBI (anti-hemophilic factor) in healthy individ-uals", Proc. Natl Acad. Sci. USA 89, 3795–3799.
   PubMed Web of Science ®Google Scholar
• Kasper, C.K. (1991) "Laboratory tests for factor VIII inhibitors, their variation, significance and interpretation", Blood Coagul. Fibrinolysis 2, 7–10.
   PubMed Web of Science ®Google Scholar
• Biggs, R., Austen, D.E., Denson, K.W., Rizza, C.R. and Borrett, R. (1972) "The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs", Br. J. Haematol. 23, 125–135.
   PubMed Web of Science ®Google Scholar
• Biggs, R., Austen, D.E., Denson, K.W., Borrett, R. and Rizza, C.R. (1972) "The mode of action of antibodies which destroy factor VBI. II. Antibodies which give complex concentration graphs", Br. J. Haematol. 23, 137–155.
   PubMed Web of Science ®Google Scholar
• Evans, RN. and Majer, R.V. (1995) "Acquired haemophilia: an important but often unrecognised cause of bleeding in elderly people", BMJ 311, 679.
   PubMed Web of Science ®Google Scholar
• Bossi, P., Cabane, J., Ninet, J., Dhote, R., Hanslik, T., Chosidow, O., Jouan-Flahault, C., Horellou, M.H., Leyna-dier, F., Liozon, E., Pouchot, J., Robin, J.P., Sanderson, F., Schaeffer, A., Sicard, D., Staikowsky, F., Wechsler, B. and Zittoun, R. (1998) "Acquired hemophilia due to factor VBI inhibitors in 34 patients", Am. J. Med. 105, 400–408.
   PubMed Web of Science ®Google Scholar
• Yee, T.T., Taher, A., Pasi, K.J. and Lee, CA. (2000) "A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period", Clin. Lab. Haematol. 22, 275–278.
   PubMedGoogle Scholar
• Hay, CR., Baglin, T.P., Collins, P.W., Hill, F.G. and Keeling, D.M. (2000) "The diagnosis and management of factor VBI and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO)", Br. J. Haematol. 111, 78–90.
   PubMed Web of Science ®Google Scholar
• Michiels, J.J., Hamulyak, K., Nieuwenhuis, H.K., Novakova, I. and van Vliet, H.H. (1997) "Acquired haemophilia A in women postpartum: management of bleeding episodes and natural history of the factor VBI inFur. J. Haematol. 59,105–109.
   Google Scholar
• Nizzi, F.A., Jr and Mues, G. (2000) "Hemorrhagic problems in obstetrics, exclusive of disseminated intravascular coagulation", Hematol. Oncol. Clin. North Am. 14, 1171–1182.
   PubMed Web of Science ®Google Scholar
• Shobeiri, S.A., West, E.C., Kahn, M.J. and Nolan, T.E. (2000) "Postpartum acquired hemophilia (factor VBI inhibitors): a case report and review of the literature", Obstet. Gynecol. Surv. 55, 729–737.
   PubMed Web of Science ®Google Scholar
• Klein, KG., Parkin, J.D. and Madaras, F. (1976) "Studies on an acquired inhibition of factor VIII induced by penicillin allergy", Clin. Exp. Immunol. 26, 155–161.
   PubMed Web of Science ®Google Scholar
• Moraca, R.J. and Ragni, M.V. (2002) "Acquired anti-FVBI inhibitors in children", Haemophilia 8, 28–32.
   PubMed Web of Science ®Google Scholar
• Alumkal, J., Rice, L., Vempathy, H., McCarthy, J.J. and Riggs, S.A. (1999) "Surgery-associated factor VBI inhibitors in patients without hemophilia", Am. J. Med. Sci. 318,350–352.
   PubMed Web of Science ®Google Scholar
• Grunewald, M., Beneke, H., Guthner, C., Germowitz, A., Brommer, A. and Griesshammer, M. (2001) "Acquired haemophilia: experiences with a standardized approach", Haemophilia 7, 164–169.
   PubMed Web of Science ®Google Scholar
• Saxena, R., Mishra, D.K., Kashyap, R., Choudhry, V.P., Mahapatra, M. and Bhargava, M. (2000) "Acquired haemophilia—a study of ten cases", Haemophilia 6, 78–83.
   PubMed Web of Science ®Google Scholar
• Morrison, A.E. and Ludlam, C.A. (1995) "Acquired haemophilia and its management", Br. J. Haematol. 89, 231–236.
   PubMed Web of Science ®Google Scholar
• Exner, T. (1995) "Diagnostic methodologies for circulating anticoagulants", Thromb. Haemost. 74, 338–344.
   PubMed Web of Science ®Google Scholar
• Sahud, MA. (2000) "Factor VBI inhibitors. Laboratory diagnosis of inhibitors", Semin. Thromb. Hemost. 26, 195–203.
   PubMed Web of Science ®Google Scholar
• Kasper, C.K., Aledort, L., Aronson, D., Counts, R., Edson, J.R., van Eys, J., Fratantoni, J., Green, D., Hampton, J., Hilgartner, M., Levine, P., Lazerson, J., McMillan, C., Penner, J., Shapiro, S. and Shulman, N.R. (1975) "Proceedings: a more uniform measurement of factor VIII inhibitors", Thromb. Diath. Haemorrh. 34, 612.
   PubMedGoogle Scholar
• Spero, J.A., Lewis, J.H. and Hasiba, U. (1981) "Corticosteroid therapy for acquired F WIC inhibitors", Br. J. Haematol. 48, 635–642.
   PubMed Web of Science ®Google Scholar
• Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., van den, B.M. and Mauser-Bunschoten, E. (1995) "The Nijmegen modification of the Bethesda assay for factor WIC inhibitors: improved specificity and reliability", Thromb. Haemost. 73, 247–251.
   PubMed Web of Science ®Google Scholar
• Erhardtsen, E. (2002) "To general haemostasis—the evidence-based route", Pathophysiol. Haemost. Thromb. 32\(Suppl. 1), 47–52.
   PubMedGoogle Scholar
• Poon, M.C. (2001) "Use of recombinant factor VlIa in hereditary bleeding disorders", Curr. Opin. Hematol. 8, 312–318.
   PubMed Web of Science ®Google Scholar
• Hedner, U., Glazer, S. and Falch, J. (1993) "Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders", Transfus. Med. Rev. 7, 78–83.
   PubMedGoogle Scholar
• Arkin, S., Blei, F., Fetten, J., Foulke, R., Gilchrist, CS., Heisel, MA., Key, N., Kisker, CT., Kitchen, C., Shafer, FE., Shah, P.C. and Strickland, D. (2000) "Human coagulation factor FVlIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors", Blood Coagul. Fibrinolysis 11, 255–259.
   Google Scholar
• Hay, CR., Negrier, C. and Ludlam, CA. (1997) "The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study", Thromb. Haemost. 78, 1463–1467.
   PubMed Web of Science ®Google Scholar
• Hedner, U. and Ingerslev, J. (1998) "Clinical use of recombinant FVlIa (rFVlIa)", Transfus. Sci. 19, 163–176.
   PubMedGoogle Scholar
• Kessler, C.M. (2000) "New products for managing inhibitors to coagulation factors: a focus on recombinant factor VlIa concentrate", Curr. Opin. Hematol. 7, 408–413.
   PubMed Web of Science ®Google Scholar
• Ludlam, C.A. (2002) "The evidence behind inhibitor treatment with recombinant factor VlIa", Pathophysiol. Haemost. Thromb. 32\(Suppl. 1), 13–18.
   PubMedGoogle Scholar
• Goudemand, J., Caron, C., Dreyfus, M. and Sie, P. (2003) "Standardization of factor VII/activated factor VII measure-ment in plasma of patients treated with recombinant factor activated VII", Blood Coagul. Fibrinolysis 14, 505–511.
   PubMed Web of Science ®Google Scholar
• Lusher, J.M. (1994) "Use of prothrombin complex concen-trates in management of bleeding in hemophiliacs with inhibitors-benefits and limitations", Semin. Hematol. 31, 49–52.
   PubMed Web of Science ®Google Scholar
• Lusher, J.M., Shapiro, S.S., Palascak, J.E., Rao, A.V., Levine, PH. and Blatt, P.M. (1980) "Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial", N. Engl. J. Med. 303, 421–425.
   PubMed Web of Science ®Google Scholar
• Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C. and Lauroua, P. (1997) "Multicenter retro-spective study on the utilization of FEIBA in France in patients with factor VBI and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity", Thromb. Haemost. 77, 1113–1119.
   PubMed Web of Science ®Google Scholar
• Kohler, M. (1999) "Thrombogenicity of prothrombin com-plex concentrates", Thromb. Res. 95, S13—S17.
   PubMed Web of Science ®Google Scholar
• Nilsson, I.M., Berntorp, E. and Freiburghaus, C. (1993) "Treatment of patients with factor VBI and IX inhibitors", Thromb. Haemost. 70, 56–59.
   PubMed Web of Science ®Google Scholar
• Gandini, G., Franchini, M., Manzato, F., Lippi, G. and Aprili, G. (1999) "A combination of prednisone, high-dose intravenous immunoglobulin and desmopressin in the treatment of acquired hemophilia A with high-titer inhibitor", Haematologica 84, 1054.
   PubMed Web of Science ®Google Scholar
• Sultan, Y. (1997) "Acquired hemophilia and its treatment", Blood Coagul. Fibrinolysis 8\(Suppl. 1), S15—S18.
   PubMedGoogle Scholar
• Mudad, R. and Kane, W.H. (1993) "DDAVP in acquired hemophilia A: case report and review of the literature", Am. J. Hematol. 43, 295–299.
   PubMed Web of Science ®Google Scholar
• de la Fuente, B., Panek, S. and Hoyer, L.W. (1985) "The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VBI inhibitor", Br. J. Haematol. 59, 127–131.
   PubMed Web of Science ®Google Scholar
• Lethagen, S. (2003) "Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety", Semin. Thromb. Hemost. 29, 101–105.
   PubMed Web of Science ®Google Scholar
• Hay, C.R. (2000) "Porcine factor VBI: past, present and future", Haematologica 85, 21–24.
   PubMedGoogle Scholar
• Kessler, C.M. and Ludlam, C.A. (1993) "The treatment of acquired factor VBI inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group", Semin. Hematol. 30, 22–27.
   PubMed Web of Science ®Google Scholar
• Hay, C.R., Lozier, J.N., Lee, C.A., Laffan, M., Tradati, E, Santagostino, E., Ciavarella, N., Schiavoni, M., Fukui, H., Yoshioka, A., Teitel, J., Mannucci, P.M. and Kasper, C.K. (1996) "Safety profile of porcine factor VBI and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey", Thromb. Haemost. 75, 25–29.
   PubMed Web of Science ®Google Scholar
• Hay, C.R. (1991) "Innovative use of porcine factor VIIIC for immune tolerance induction", Am. J. Med. 91, 27S–29S.
   PubMed Web of Science ®Google Scholar
• Gringeri, A., Santagostino, E., Tradati, E, Giangrande, and Mannucci, P.M. (1991) "Adverse effects of treatment with porcine factor VBI", Thromb. Haemost. 65, 245–247.
   PubMed Web of Science ®Google Scholar
• Astermark, J. (2003) "Treatment of the bleeding inhibitor patient", Semin. Thromb. Hemost. 29, 77–86.
   PubMed Web of Science ®Google Scholar
• Green, D., Rademaker, A.W. and Briet, E. (1993) "A prospective randomised trial of prednisolone and cyclophosphamide in the treatment of patients with factor VBI autoantibodies", Thromb. Haemost. 70, 753–757.
   PubMed Web of Science ®Google Scholar
• Freedman, J., Rand, M.L., Russell, O., Davis, C., Cheatley, PL., Blanchette, V. and Garvey, M.B. (2003) "Immuno-adsorption may provide a cost-effective approach to management of patients with inhibitors to FVBI", Trans-fusion 43, 1508–1513.
   PubMed Web of Science ®Google Scholar
• Lian, E.C., Larcada, A.F. and Chiu, A.Y. (1989) "Combination immunosuppressive therapy after factor VBI infusion for acquired factor VBI inhibitor", Ann. Intern. Med. 110, 774–778.
   PubMed Web of Science ®Google Scholar
• Bayer, R.L., Lichtman, S.M., Allen, S.L., Budman, D.R., Buchbinder, A., Fetten, J., Kolitz, J. and Loscalzo, J. (1999) "Acquired factor VBI inhibitors—successful treatment with an oral outpatient regimen", Am. J. Hematol. 60, 70–71.
   PubMed Web of Science ®Google Scholar
• Green, D. (1998) "Oral immunosuppressive therapy for acquired hemophilia", Ann. Intern. Med. 128, 325.
   PubMed Web of Science ®Google Scholar
• Shaffer, L.G. and Phillips, M.D. (1997) "Successful treatment of acquired hemophilia with oral immunosuppressive therapy", Ann. Intern. Med. 127, 206–209.
   PubMed Web of Science ®Google Scholar
• Sultan, Y., Kazatchkine, M.D., Maisonneuve, P. and Nydegger, U.E. (1984) "Anti-idiotypic suppression of autoantibodies to factor VBI (antihaemophilic factor) by high-dose intravenous gammaglobulin", Lancet 2, 765–768.
   PubMed Web of Science ®Google Scholar
• Green, D. and Kwaan, H.C. (1987) "An acquired factor VBI inhibitor responsive to high-dose gamma globulin", Thromb. Haemost. 58, 1005–1007.
   PubMed Web of Science ®Google Scholar
• Sultan, Y, Kazatchkine, M.D., Nydegger, U., Rossi, F., Dietrich, G. and Algiman, M. (1991) "Intravenous immuno-globulin in the treatment of spontaneously acquired factor VIIIC inhibitors", Am. J. Med. 91, 35S–39S.
   Google Scholar
• Dykes, A.C., Walker, ID., Lowe, G.D. and Tait, R.C. (2001) "Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review", Haemophilia 7, 160–163.
   PubMed Web of Science ®Google Scholar
• Von Depka, M. and Huth-Kuhne, A. (2003) "Immuno-adsorption with anti-immunoglobulin antibodies using Ig-TheraSorb columns", In: Rodriguez-Merchan EC, L.C., ed., Inhibitors in Patients with Haemophilia (Oxford, UK 2002) (Blackwell Science), pp 199–205.
   Google Scholar
• Guillet, B., Kriaa, E, Huysse, M.G., Proulle, V, George, C., Tchernia, G., D'Oiron, R., Laurian, Y, Charpentier, B., Lambert, T. and Dreyfus, M. (2001) "Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia", Br. J. Haematol. 114, 837–844.
   PubMed Web of Science ®Google Scholar
• Negrier, C., Dechavanne, M., Alfonsi, E and Tremisi, P.J. (1991) "Successful treatment of acquired factor VBI antibody by extracorporeal immunoadsorption", Acta Haematol. 85, 107–110.
   PubMed Web of Science ®Google Scholar
• Hambley, H., Watkins, R., Tansey, P.A., Walker, ID. and Davidson, J.F. (1985) "Plasmapheresis and Factor VBIC inhibitors", Lancet 1, 274.
   PubMed Web of Science ®Google Scholar
• Schwerdtfeger, R., Hintz, G. and Huhn, D. (1991) "Successful treatment of a patient with postpartum factor VBI inhibitor with recombinant human interferon alpha 2a", Am. J. Hematol. 37, 190–193.
   PubMed Web of Science ®Google Scholar
• Castenskiold, E.C., Colvin, B.T. and Kelsey, S.M. (1994) "Acquired factor VBI inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A", Br. J. Haematol. 87, 434–436.
   PubMed Web of Science ®Google Scholar
• English, K.E., Brien, W.F., Howson-Jan, K. and Kovacs, M.J. (2000) "Acquired factor VBI inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy", Ann. Pharmacother. 34, 737–739.
   PubMed Web of Science ®Google Scholar
• White, G.C., Greenwood, R., Escobar, M. and Frelinger, J.A. (2000) "Hemophilia factor VBI therapy. Immunological tolerance. A clinical perspective", Haematologica 85, 113–116.
   PubMedGoogle Scholar
• DiMichele, D.M. and Kroner, B.L. (2002) "The North American Immune Tolerance Registry: practices, outcomes, outcome predictors", Thromb. Haemost. 87, 52–57.
   PubMed Web of Science ®Google Scholar
• Mariani, G. and Kroner, B. (2001) "Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success", Haematologica 86, 1186–1193.
   PubMed Web of Science ®Google Scholar
• Lenk, H. (2000) "The German Registry of immune tolerance treatment in hemophilia-1999 update", Haematologica 85, 45–47.
   PubMedGoogle Scholar
• Hay, C.R., Colvin, B.T., Ludlam, CA., Hill, F.G. and Preston, EE. (1996) "Recommendations for the treatment of factor VBI inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party", Blood Coagul. Fibrinolysis 7, 134–138.
   PubMed Web of Science ®Google Scholar
• Mariani, G., Siragusa, S. and Kroner, B.L. (2003) "Immune tolerance induction in hemophilia A: a review", Semin. Thromb. Hemost. 29, 69–75.
   PubMed Web of Science ®Google Scholar
• Hay, C.R. (2000) "Hemophilia treatment. Immune tolerance induction: prospective clinical trials", Haematologica 85, 52–55.
   PubMedGoogle Scholar
• Hay, C.R.M. (2001) "A prospective, international, random-ised comparison of high- and low-dose immune tolerance induction in haemophilia A", Thromb. Haemost., abs 5Y2410.
   Google Scholar
• Kreuz, W., Ehrenforth, S., Funk, M., Auerswald, G., Mentzer, D., Joseph-Steiner, J., Beeg, T., Klarmann, D., Scharrer, I. and Kornhuber, B. (1995) "Immune tolerance therapy in paediatric haemophiliacs with factor VBI inhibitors: 14 years follow-up", Haemophilia 1, 24–32.
   PubMed Web of Science ®Google Scholar
• Berntorp, E. (2001) "Immune tolerance induction: recombi-nant vs. human-derived product", Haemophilia 7, 109–113.
   PubMed Web of Science ®Google Scholar
• Batlle, J., Lopez, M.F., Brackmann, H.H., Gaillard, S., Goudemand, J., Humbert, J., De Moerloose, P., Maass, E., Mauz-Korholz, C., Sultan, Y. and Stieltjes, N. (1999) "Induction of immune tolerance with recombinant factor VBI in haemophilia A patients with inhibitors", Haemophilia 5,431–435.
   PubMed Web of Science ®Google Scholar
• International Immune Tolerance Induction Study (2003). Available at: http://www.itistudy.com. Accessed 1-2–0004.
   Google Scholar
• Ho, A.Y., Height, S.E. and Smith, M.P. (2000) "Immune tolerance therapy for haemophilia", Drugs 60, 547–554.
   PubMed Web of Science ®Google Scholar
• Brackmann, H.H. (1984) "Induced immunotolerance in factor VBI inhibitor patients", Prog. Clin. Biol. Res. 150, 181–195.
   PubMedGoogle Scholar
• Mauser-Bunschoten, E.P., Nieuwenhuis, H.K., Roosendaal, G. and Van Den Berg, H.M. (1995) "Low-dose immune tolerance induction in hemophilia A patients with inhibi-tors", Blood 86, 983–988.
   PubMed Web of Science ®Google Scholar
• Nilsson, I.M., Berntorp, E. and Zettervall, O. (1988) "Induction of immune tolerance in patients with hemophilia and antibodies to factor VBI by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII", N. Engl. J. Med. 318, 947–950.
   PubMed Web of Science ®Google Scholar
• German Medical Council (2002). Guidelines for therapy with blood components and blood derivatives. Available at: http://www.bundesaerztekammer.de. Accessed 1-2–2004.
   Google Scholar
• Berntorp, E. and Nilsson, I.M. (1996) "Immune tolerance and the immune modulation protocol", Vox Sang 70\(Suppl. 1), 36–41.
   PubMedGoogle Scholar
• Mansouri-Taleghani, B., Grossman, R., Keller, F. and Wiebecke, D. (1998) "Therapy of coagulation factor VBI autoantibodies with long-term extracorporeal protein A adsorption and immunosuppression", Transfus. Sci. 19, 39–42.
   Google Scholar
• Zeitler, H., Unkrig, C. and Brackmann, H. (1997) "An immunomodulatory treatment of acquired hemophilia A with longterm IgG IA, immunosuppression, and antigen substitution—a modified Bonn protocol inducing immune tolerance", Blood 90\(Suppl. 1), abs 36A.
   Google Scholar
• Huth-Kuhne, A., Ehrenforth, S., Scharrer, I. and Zimmermann, R. (2000) "A new therapeutic protocol for a rapid FVBI inhibitor elimination in acquired hemophilia", Blood 96, abs 268a.
   Web of Science ®Google Scholar
• Von Depka, M., Varvenne, M., Eisert, R., Wermes, C. and Ganser, A. (2002) "Immune tolerance treatment with B-Domain Deleted recombinant FVBI (BDD-rFVBI, ReFacto) in patients with acquired hemophilia", Blood 100, abs 2755.
   Web of Science ®Google Scholar
• Berntorp, E. (1997) "Second generation, B-domain deleted recombinant factor VIII", Thromb. Haemost. 78, 256–260.
   PubMed Web of Science ®Google Scholar
• Sandberg, H., Almstedt, A., Brandt, J., Castro, V.M., Gray, E., Holmquist, L., Lewin, M., Oswaldsson, U., Mikaelsson, M., Jankowski, M.A., Bond, M. and Scoble, H.A. (2001) "Structural and functional characterization of B-domain deleted recombinant factor VBI", Semin. Hematol. 38, 4–12.
   PubMed Web of Science ®Google Scholar
• Lusher, J.M., Lee, C.A., Kessler, C.M. and Bedrosian, C.L. (2003) "The safety and efficacy of B-domain deleted recombinant factor VBI concentrate in patients with severe haemophilia A", Haemophilia 9, 38–49.
   PubMed Web of Science ®Google Scholar
• Lind, P., Larsson, K., Spira, J., Sydow-Backman, M., Almstedt, A., Gray, E. and Sandberg, H. (1995) "Novel forms of B-domain-deleted recombinant factor VBI mole-cules. Construction and biochemical characterization", Fur. J. Biochem. 232, 19–27.
   Web of Science ®Google Scholar
• Pipe, S.W., Morris, J.A., Shah, J. and Kaufman, R.J. (1998) "Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin", J. Biol. Chem. 273, 8537–8544.
   PubMed Web of Science ®Google Scholar
• Pittman, D.D., Alderman, E.M., Tomkinson, K.N., Wang, J.H., Giles, A.R. and Kaufman, R.J. (1993) "Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VBI", Blood 81, 2925–2935.
   PubMed Web of Science ®Google Scholar
• Courter, S.G. and Bedrosian, C.L. (2001) "Clinical evaluation of B-domain deleted recombinant factor VBI in previously treated patients", Semin. Hematol. 38, 44–51.
   PubMed Web of Science ®Google Scholar